Philips LumiGuide 3D device guidance in use Philips LumiGuide 3D device guidance in use December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands an ...

Core Viewpoint - Royal Philips has announced the expanded commercial availability of LumiGuide 3D Device Guidance, the first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States, marking a significant advancement in radiation-free navigation technology [2][10]. Group 1: Product Overview - LumiGuide allows physicians to visualize and guide devices inside the body using light instead of continuous X-ray, enhancing radiation safety and dose reduction in image-guided therapy [2][5]. - The technology integrates seamlessly with Philips' Azurion platform, which is designed to drive procedural innovation across various clinical domains [3][9]. - LumiGuide utilizes Fiber Optic RealShape (FORS) technology to provide high-resolution, full-color images in real-time, enabling precise navigation during complex endovascular procedures [5][8]. Group 2: Clinical Impact - Clinical experiences indicate that LumiGuide can improve efficiency, reduce procedure time, and minimize fluoroscopy pedal usage, with complex aortic repair procedures performed 37% faster and with up to 56% reduction in dose area product (DAP) [4][5]. - Over 2,000 clinical procedures have utilized LumiGuide, demonstrating its effectiveness and integration with the Azurion platform [10]. Group 3: Market Expansion - Following a successful limited market release in late 2023, LumiGuide will be commercially available from January 2026 in key European markets and the United States, expanding access to advanced image-guided therapy [10][14]. - Philips aims to enhance the adoption of this technology in hospitals to improve treatment precision and safety while reducing radiation risks for both patients and clinical staff [6][7]. Group 4: Commitment to Safety - LumiGuide is part of Philips' broader portfolio aimed at reducing or eliminating radiation exposure during image-guided procedures, reinforcing the company's leadership in low- and no-dose interventional solutions [11][14]. - The integration of LumiGuide with other technologies like Azurion with ClarityIQ and DoseAware further emphasizes Philips' commitment to advancing radiation safety in medical procedures [11].

Core Insights - Royal Philips has introduced the BlueSeal Horizon, the first helium-free 3.0T MRI platform, marking a significant advancement in MRI technology [1][11][12] - The new platform aims to enhance diagnostic capabilities while reducing reliance on helium, a resource that is becoming increasingly scarce [3][4] Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation [9][10] - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people across more than 100 countries [10] Technological Advancements - The BlueSeal Horizon platform eliminates the need for helium refills and vent pipes, simplifying installation and reducing lifecycle risks [2][4] - Key features of the platform include SmartPlanning, which automates planning steps for cardiac imaging, and Real-time Scan Preview, which allows radiologists to adjust image quality in real time [4][5] - SmartSpeed Precise technology enables scans to be up to three times faster and images to be up to 80% sharper, enhancing diagnostic efficiency [6][8] Environmental Impact - Philips has saved over 6 million liters of liquid helium by implementing helium-free technology in its 1.5T BlueSeal MRI systems, and aims to extend these benefits to the 3.0T MRI systems [2][8]

Core Insights - Royal Philips has launched the BlueSeal Horizon, a new 3.0T MRI platform featuring the first helium-free 3.0T magnet, marking a significant advancement in MRI technology [1][2][3] Group 1: Technological Advancements - The BlueSeal Horizon platform eliminates the need for helium refills and vent pipes, reducing installation complexity and lifecycle risks [2] - The platform integrates advanced AI capabilities to enhance diagnostic precision and streamline workflows, allowing for faster and more efficient imaging processes [4][5][6] Group 2: AI Innovations - Key AI features include SmartPlanning, which automates planning steps for cardiac imaging, completing tasks in as little as 30 seconds [4] - Real-time Scan Preview enables faster 3D image reconstruction and allows radiologists to adjust image quality in real time [5] - SmartSpeed Precise technology allows scans to be up to three times faster and images to be up to 80% sharper, improving detail capture [6] Group 3: Market Impact - The introduction of the BlueSeal Horizon aims to expand access to advanced imaging technologies, particularly for underserved populations [3][7] - Philips has already installed over 2,000 of its 1.5T BlueSeal MRI systems globally, saving more than 6 million liters of liquid helium [2][8]